|Mr. Michael A. Narachi M.S., M.B.A.||Pres, Chief Exec. Officer & Director||1.15M||N/A||58|
|Dr. Thomas R. Cannell D.V.M.||Exec. VP, COO & Pres of Global Commercial Products||691.11k||N/A||55|
|Mr. Thomas P. Lynch||Exec. VP, Gen. Counsel & Sec.||552.37k||N/A||50|
|Mr. Jason Keyes||Sr. VP & CFO||N/A||N/A||46|
|Stephen A. Moglia||Chief Accounting Officer, VP and Controller||N/A||N/A||N/A|
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Orexigen Therapeutics, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 8.